Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial

被引：0

作者：

Kappos, L. ^{[1
,2
]}

Bar-Or, A. ^{[3
]}

Cree, B. ^{[4
]}

Fox, R. ^{[5
]}

Giovannoni, G. ^{[6
]}

Gold, R. ^{[7
]}

Vermersch, P. ^{[8
]}

Lam, E. ^{[9
]}

Pohlmann, H. ^{[9
]}

Zhang-Auberson, L. ^{[9
]}

Dandekar, A. ^{[9
]}

Wallstrom, E. ^{[9
]}

机构：

[1] Univ Basel Hosp, Dept Neurol, CH-4031 Basel, Switzerland

[2] Univ Basel Hosp, Dept Biomed, CH-4031 Basel, Switzerland

[3] McGill Univ, Montreal Neurol Inst & Hosp, Neuroimmunol Unit, Montreal, PQ, Canada

[4] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA

[5] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA

[6] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England

[7] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

[8] Univ Lille Nord France, Dept Neurol, Lille, France

[9] Novartis Pharma AG, Basel, Switzerland

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-53

引用

页码：927 / 928

页数：2

共 50 条

[41] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
Mao-Draayers, Yang
Wu, Qi
Wang, Qin
Dowling, Catherine
Lundy, Steven
Segal, Benjamin
Wallstrom, Wallstrom
[J]. NEUROLOGY, 2016, 86
[42] Baseline immunological profile in secondary progressive multiple sclerosis patients of Phase III EXPAND Trial
Mao-Draayer, Yang
Wu, Qi
Wang, Qin
Dowling, Catherine
Lundy, Steve K.
Segal, Benjamin Matthew M.
Wallstroem, Erik
Fox, David A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 13 - 13
[43] Baseline Immunological Profile in Secondary Progressive Multiple Sclerosis Patients of Phase III EXPAND Trial
Mao-Draayer, Yang
Wu, Qi
Wang, Qin
Lundy, Steve K.
Dowling, Catherine
Segal, Benjamin Matthew M.
Fox, David
Wallstroem, Erik
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 12 - 12
[44] Progressive multifocal leukoencephalopathy in association with siponimod treatment for secondary progressive multiple sclerosis: a case report
Rot, Uros
Jerala, Miha
Ledinek, Alenka Horvat
Jakob, Gregor Brecl
[J]. JOURNAL OF NEUROLOGY, 2024, 271 (08) : 4794 - 4812
[45] COST EFFECTIVENESS OF SIPONIMOD FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN TURKEY
Tatar, M.
Osbalas, T.
Saracoglu, B.
Olmez, C.
Yarci, B.
Akdernir, A. C.
Yilmaz, C.
Sen, S.
[J]. VALUE IN HEALTH, 2022, 25 (12) : S184 - S184
[46] Siponimod (BAF312) Treatment Reduces Brain Infiltration but Not Lesion Volume in Middle-Aged Mice in Experimental Stroke
Vogelgesang, Antje
Domanska, Grazyna
Ruhnau, Johanna
Dressel, Alexander
Kirsch, Michael
Schulze, Juliane
[J]. STROKE, 2019, 50 (05) : 1224 - 1231
[47] Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution
Sarr, C.
Savelieva, M.
Ette, G.
Petry, C.
Legangneux, E.
Wallstroem, E.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 89 - 89
[48] Safety and Tolerability of Siponimod in Patients with Secondary Progressive Multiple Sclerosis
Fox, Robert
Kappos, Ludwig
Bar-Or, Amit
Cree, Bruce
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Pohlmann, Harold
Wolf, Christian
Dahlke, Frank
Wallstrom, Erik
Sidorenko, Tatiana
[J]. NEUROLOGY, 2017, 88
[49] Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
Cree, Bruce A. C.
Magnusson, Baldur
Rouyrre, Nicolas
Fox, Robert J.
Giovannoni, Gavin
Vermersch, Patrick
Bar-Or, Amit
Gold, Ralf
Piani Meier, Daniela
Karlsson, Goril
Tomic, Davorka
Wolf, Christian
Dahlke, Frank
Kappos, Ludwig
[J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (10) : 1564 - 1576
[50] Modeling dose-PK-lymphocytes relationship under siponimod (BAF312) treatment to infer time to immune reconstitution
Sarr, C.
Savelieva, M.
Ette, G.
Petry, C.
Legangneux, E.
Wallstroem, E.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 447 - 447

← 1 2 3 4 5 →